Drugs / Lipidem
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00497289 | Jan 2006 → Feb 2008 | parenteral nutrition-associated cholestasis, pulmonary immaturity | B. Braun Melsungen AG | Completed | Missed primary |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT03282955 | Jan 2018 → Jul 2022 | — | B. Braun Melsungen AG | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02550860 Comparator | Jan 2015 → Sep 2017 | intestinal disorder | Hospices Civils de Lyon | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lipidem | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00497289 ↗ |
| Known as | fish oil (FO)-containing IVFE | “fish oil (FO)-containing IVFE (Lipidem)” NCT02550860 ↗ |
| Modality | Other / unclassified | “fish oil (FO)-containing IVFE” NCT02550860 ↗ |
| Route | Intravenous | “daily i.v. infusion for up to 5 days” NCT00497289 ↗ |